drugset / Trial / NCT05918588

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918588

Phase 1 Completed 32 enrolled Kadmon, a Sanofi Company
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.

Timeline

Start
2013-11-21
Primary completion
2014-03-06
Completion
2014-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Belumosudil Small molecule 500 mg Oral
Subject Belumosudil Small molecule 800 mg Oral
Subject Belumosudil Small molecule 1000 mg Oral